Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary M Prendergast

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Quantifying costs associated with atopic dermatitisCharles N Ellis, Mary M Prendergast, Michael Tokar, et al.
The Journal of Investigative Dermatology|August 12, 2004
Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatologyMary M Prendergast, William Abramovits, Mark Boguniewicz, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|July 4, 2003
The PORTEL registry: overview and selected findingsDonna Hathaway, Mark L Barr, R Mark Ghobrial, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|July 4, 2003
Assessing quality-of-life outcomes in organ transplant recipients: progress and prioritiesDonna Hathaway, Mark L Barr, R Mark Ghobrial, et al.
Pharmacoeconomics|June 18, 2005
The economics of topical immunomodulators for the treatment of atopic dermatitisWilliam Abramovits, Mark Boguniewicz, Amy S Paller, et al.
Pharmacoeconomics|August 12, 2003
Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczemaCharles N Ellis, Lynn A Drake, Mary M Prendergast, et al.
Journal of the American Academy of Dermatology|March 29, 2003
Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitisCharles N Ellis, Lynn A Drake, Mary M Prendergast, et al.
Journal of the American Academy of Dermatology|February 28, 2002
Cost of atopic dermatitis and eczema in the United StatesCharles N Ellis, Lynn A Drake, Mary M Prendergast, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Quantifying costs associated with atopic dermatitisCharles N Ellis, Mary M Prendergast, Michael Tokar, et al.
The Journal of Investigative Dermatology|August 12, 2004
Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatologyMary M Prendergast, William Abramovits, Mark Boguniewicz, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|July 4, 2003
The PORTEL registry: overview and selected findingsDonna Hathaway, Mark L Barr, R Mark Ghobrial, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|July 4, 2003
Assessing quality-of-life outcomes in organ transplant recipients: progress and prioritiesDonna Hathaway, Mark L Barr, R Mark Ghobrial, et al.
Pharmacoeconomics|June 18, 2005
The economics of topical immunomodulators for the treatment of atopic dermatitisWilliam Abramovits, Mark Boguniewicz, Amy S Paller, et al.
Pharmacoeconomics|August 12, 2003
Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczemaCharles N Ellis, Lynn A Drake, Mary M Prendergast, et al.
Journal of the American Academy of Dermatology|March 29, 2003
Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitisCharles N Ellis, Lynn A Drake, Mary M Prendergast, et al.
Journal of the American Academy of Dermatology|February 28, 2002
Cost of atopic dermatitis and eczema in the United StatesCharles N Ellis, Lynn A Drake, Mary M Prendergast, et al.
Pageof 1